Production and Release Testing of Ovine Atadenovirus Vectors

  • Gerald W. Both
  • Fiona Cameron
  • Anne Collins
  • Linda J. Lockett
  • Jan Shaw
Part of the Methods in Molecular Medicine book series (MIMM, volume 130)


Gene-directed enzyme prodrug therapy (GDEPT) is an emerging approach for the treatment of cancers. A variety of viral vectors have been used to deliver genes that encode the relevant enzymes, and some have been tested in clinical trials. To ensure the potency and efficacy of such vectors and to obtain regulatory approval to administer them to humans, it is necessary to develop a suite of assays that provide quality assurance. New GDEPT vectors based on ovine atadenovirus and Escherichia coli purine nucleoside phosphorylase (PNP) have been developed for first time use in humans in a phase I trial for the treatment of prostate cancer. Here we describe methods for their production together with several quality-control assays. In particular, a functional cell killing assay was devised to measure the potency of PNP-GDEPT vectors, the principles of which could easily be adapted to other systems.

Key Words

Ovine atadenovirus vectors PNP-GDEPT prostate cancer 


  1. 1.
    Curiel, D. and Douglas, J., eds. (2002) Adenoviral Vectors for Gene Therapy. Academic Press, San Diego, CA.Google Scholar
  2. 2.
    Both, G. (2002) Xenogenic adenoviruses, in Adenoviral Vectors for Gene Therapy (Curiel, D. and Douglas, J., eds.), Academic Press, San Diego, CA, pp. 447–479.CrossRefGoogle Scholar
  3. 3.
    Benko, M. and Harrach, B. (1998) A proposal for a new (third) genus within the family Adenoviridae. Arch. Virol. 143, 829–837.PubMedCrossRefGoogle Scholar
  4. 4.
    Both, G. W. (2004). Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol. Cell Biol. 82, 189–195.PubMedCrossRefGoogle Scholar
  5. 5.
    Voeks, D., Martiniello-Wilks, R., Madden, V., et al. (2002) Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 9, 759–768.PubMedCrossRefGoogle Scholar
  6. 6.
    Martiniello-Wilks, R., Dane, A., Voeks, D. J., et al. (2004) Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J. Gene Med. 6, 43–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Martiniello-Wilks, R., Wang, X.-Y., Voeks, D., et al. (2004) Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J. Gene Med. 6, 1343–1357.PubMedCrossRefGoogle Scholar
  8. 8.
    Wang, X.-Y., Martiniello-Wilks, R., Shaw, J., et al. (2004) Preclinical evaluation of a prostate targeted gene directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther. 11, 1559–1567.PubMedCrossRefGoogle Scholar
  9. 9.
    Vrati, S., Macavoy, E. S., Xu, Z. Z., Smole, C., Boyle, D. B., and Both, G. W. (1996) Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses. Virology 220, 200–203.PubMedCrossRefGoogle Scholar
  10. 10.
    Löser, P., Hofmann, C., Both, G. W., Uckert, W., and Hillgenberg, M. (2003) Construction, rescue, and characterization of vectors derived from ovine atadenovirus. J. Virol. 77, 11,941–11,951.PubMedCrossRefGoogle Scholar
  11. 11.
    Löser, P., Kümin, D., Hillgenberg, M., Both, G., and Hofmann, C. (2001) Preparation of ovine adenovirus vectors. In Methods in Molecular Medicine, Gene Therapy Protocols, 2nd ed. (Morgan, J., ed.), Humana Press, Totowa, NJ, Vol. 69, pp. 415–426.Google Scholar
  12. 12.
    Cameron, F. H., Moghaddam, M. J., Bender, V. J., Whittaker, R. G., Mott, M., and Lockett, T. J. (1999) A transfection compound series based on a versatile tris linkage. Biochim. Biophys. Acta 1417, 37–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Fasbender, A., Zabner, J., Chillon, M., et al. (1997) Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J. Biol. Chem. 272, 6479–6489.PubMedCrossRefGoogle Scholar
  14. 14.
    Schagen, F. H. E., Rademaker, H. J., Rabelink, M. J., et al. (2000) Ammonium sulphate precipitation of recombinant adenovirus from culture medium: an easy method to increase the total virus yield. Gene Ther. 7, 1570–1574.PubMedCrossRefGoogle Scholar
  15. 15.
    Mittereder, N., March, K. L., and Trapnell, B. C. (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498–7509.PubMedGoogle Scholar
  16. 16.
    Maizel, J. V., White, D. O., and Scharff, M. D. (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115–125.PubMedCrossRefGoogle Scholar
  17. 17.
    Spearman, C. (1908) The method of right and wrong cases (constant stimuli) without Gauss formulae. Br. J. Psychol. 2, 227–242.Google Scholar
  18. 18.
    Karber, G. (1931) Beitrag zur kollectiven Behandlung phamakalogischer Reihenversuche. Arch. Exp. Pharmak. 162, 480–487.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Gerald W. Both
    • 1
  • Fiona Cameron
    • 1
  • Anne Collins
    • 2
  • Linda J. Lockett
    • 1
  • Jan Shaw
    • 1
  1. 1.CSIRO Molecular and Health TechnologiesNorth RydeAustralia
  2. 2.Virient Party Ltd.ThebartonAustralia

Personalised recommendations